title: Association of circulating levels of RANTES and -403G/A promoter polymorphism to acute heart failure after STEMI and to cardiogenic shock.
abstract: Chemokines, including RANTES, play a crucial role in the processes of inflammation during cardiovascular disorders, including myocardial infarction, disease progression and complications. This study aimed to evaluate the role of RANTES -403G/A polymorphism and levels in circulation in processes of development and progression of myocardial infarction and cardiogenic shock. A total of 609 patients with ST-segment elevation myocardial infarction, 43 patients with cardiogenic shock and 130 control subjects were enrolled in the study. RANTES -403G/A promoter polymorphism and baseline serum RANTES levels were analyzed. In the present study, we associated RANTES -403G/A promoter polymorphism with acute heart failure in patients with myocardial infarction (p = 0.006) and ejection fraction 3 months after MI onset (p = 0.02). Further, a difference in circulating RANTES levels among controls and STEMI subjects, and a relation of serum levels with acute heart failure was observed (p = 0.03, p = 0.003, respectively). We found a significant difference when comparing cardiogenic shock patients and controls (p < 0.001), with the most significant difference between cardiogenic shock and AHF subgroup of STEMI patients (p < 0.001). We observed a decreasing tendency of serum RANTES levels with the severity of myocardial infarction and progression, with the lowest levels in patients with cardiogenic shock (cutoff level ≥80.4 ng/ml). Our results suggest the role of RANTES as a potential biomarker of cardiogenic shock and acute heart failure in the hospital phase after myocardial infarction.
authors.affiliation: Faculty of Medicine, Institute of Pathological Physiology, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic.
authors.forename: Jolana
authors.initials: J
authors.lastname: Lipkova
authors.forename: Jiri
authors.initials: J
authors.lastname: Parenica
authors.forename: Kamil
authors.initials: K
authors.lastname: Duris
authors.forename: Katerina
authors.initials: K
authors.lastname: Helanova
authors.forename: Josef
authors.initials: J
authors.lastname: Tomandl
authors.forename: Lenka
authors.initials: L
authors.lastname: Kubkova
authors.forename: Anna
authors.initials: A
authors.lastname: Vasku
authors.forename: Monika
authors.initials: M
authors.lastname: Goldbergova Pavkova
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D018946:Chemokine CCL5 / Q000097:blood* / Q000235:genetics*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006333:Heart Failure / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012770:Shock, Cardiogenic / Q000097:blood / Q000235:genetics* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D015415:Biomarkers; D018946:Chemokine CCL5